Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 15, Issue 5, pp. 521-531
PubMed
Published By
Print ISSN
Online ISSN
History
- Received September 22, 2016
- Revision received December 3, 2016
- Accepted December 22, 2016
- Published first January 24, 2017.
Article Versions
- Previous version (January 24, 2017 - 12:58).
- You are viewing the most recent version of this article.
Copyright & Usage
©2017 American Association for Cancer Research.
Author Information
- Michael D. Nyquist1,
- Alexandra Corella1,
- John Burns2,
- Ilsa Coleman1,
- Shuai Gao3,4,
- Robin Tharakan1,
- Luke Riggan1,
- Changmeng Cai3,4,
- Eva Corey5,
- Peter S. Nelson1,5,6, and
- Elahe A. Mostaghel6,7,*
- 1Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington.
- 2Virginia Mason Medical Center, Seattle, Washington.
- 3Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.
- 4Hematology-Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
- 5Department of Urology, University of Washington, Seattle, Washington.
- 6Division of Oncology, Department of Medicine, University of Washington, Seattle, Washington.
- 7Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
- ↵*Corresponding Author:
Elahe A. Mostaghel, University of Washington, 1100 Fairview Avenue N, P.O. Box 19024, Seattle, WA 98109. Phone: 206-667-2746; Fax: 206-667-2917; E-mail: emostagh{at}fredhutch.org
May 2017
Volume 15, Issue 5
Volume 15, Issue 5
Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155
Jump to section
Advertisement